OTCMKTS:CYAN Cyanotech (CYAN) Stock Price, News & Analysis $0.53 +0.13 (+32.53%) As of 10/6/2026 03:48 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Cyanotech Stock (OTCMKTS:CYAN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cyanotech alerts:Sign Up Key Stats Today's Range$0.50▼$0.5550-Day Range$0.35▼$0.5352-Week Range$0.23▼$0.57Volume17,025 shsAverage Volume3,940 shsMarket Capitalization$4.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cyanotech Corporation is a biotechnology company that cultivates and processes microalgae for use in nutritional supplements, functional foods, and natural ingredients. The company operates from the Kona coast of Hawaii, where its production facilities use open-pond cultivation to grow algae in a controlled environment. Its principal products include Hawaiian Spirulina Pacifica, a spirulina-based nutritional supplement, and BioAstin Hawaiian Astaxanthin, a natural astaxanthin product derived from the microalga Haematococcus pluvialis. Cyanotech has also developed other algae-based ingredients and formulations for consumer and commercial applications. Founded in 1969, Cyanotech has focused on commercial microalgae production and the development of algae-derived health and wellness products. Its products have been marketed through retail, direct-to-consumer, and commercial distribution channels in the United States and internationally.AI Generated. May Contain Errors. Read More Cyanotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreCYAN MarketRank™: Cyanotech scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cyanotech. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyanotech is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyanotech is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyanotech has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Cyanotech has been sold short.Short Interest Ratio / Days to CoverCyanotech has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyanotech has recently increased by 3.83%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyanotech does not currently pay a dividend.Dividend GrowthCyanotech does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentCyanotech has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cyanotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Cyanotech to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyanotech insiders have not sold or bought any company stock.Percentage Held by Insiders34.40% of the stock of Cyanotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions24.40% of the stock of Cyanotech is held by institutions.Read more about Cyanotech's insider trading history. Receive CYAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYAN Stock News HeadlinesCyanotech (OTCMKTS:CYAN) Shares Cross Below 200-Day Moving Average - Here's What HappenedOctober 1, 2026 | americanbankingnews.comCyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2024May 20, 2026 | finanznachrichten.deThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Spirulina Extract Market | 6.0% CAGR | Asia Pacific, USA, Europe Lead | DIC Corp, Cyanotech, Parry Nutraceuticals Drive Clean-Label RevolutionApril 8, 2026 | finance.yahoo.comCyanotech Corp.February 13, 2026 | marketwatch.comCyanotech Corp (CYAN) Q2 2026 Earnings Call Highlights: Revenue Surge and Margin Expansion ...November 19, 2025 | finance.yahoo.comCyanotech Corporation (CYAN) Q2 2026 Earnings Call Prepared Remarks TranscriptNovember 11, 2025 | seekingalpha.comCyanotech Reports Financial Results for the Second Quarter of Fiscal 2026November 10, 2025 | businesswire.comSee More Headlines CYAN Stock Analysis - Frequently Asked Questions How have CYAN shares performed this year? Cyanotech's stock was trading at $0.45 on January 1st, 2026. Since then, CYAN stock has increased by 17.8% and is now trading at $0.5301. How were Cyanotech's earnings last quarter? Cyanotech Co. (OTCMKTS:CYAN) released its quarterly earnings results on Monday, June, 29th. The biotechnology company reported $0.00 earnings per share (EPS) for the quarter. Cyanotech had a negative trailing twelve-month return on equity of 0.86% and a negative net margin of 0.25%. How do I buy shares of Cyanotech? Shares of CYAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cyanotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL). Company Calendar Last Earnings6/29/2026Today10/07/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:CYAN CIK768408 Webwww.cyanotech.com Phone(808) 326-1353Fax808-329-4533Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.28 million Net Margins-0.25% Pretax Margin-0.23% Return on Equity-0.86% Return on Assets-0.30% Debt Debt-to-Equity Ratio0.13 Current Ratio1.06 Quick Ratio0.39 Sales & Book Value Annual Sales$26.59 million Price / Sales0.15 Cash Flow$0.11 per share Price / Cash Flow4.82 Book Value$1.04 per share Price / Book0.51Miscellaneous Outstanding Shares7,670,000Free Float5,032,000Market Cap$4.07 million OptionableNot Optionable Beta0.04 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:CYAN) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyanotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyanotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.